{"analyses":[{"ciLowerLimit":"-14.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-2.13","groupDescription":"Stratification factors: Enrollment stage, PD-L1 status, Bajorin risk score/presence of liver metastases, and investigator choice of chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0083","paramType":"Difference in Event Free Rate","paramValue":"-8.29","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.93","upperLimit":"26.42","value":"22.17"},{"groupId":"OG001","lowerLimit":"26.00","upperLimit":"34.93","value":"30.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"451"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) Event Free Rate at Year 1","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG001","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"}],"paramType":"NUMBER","populationDescription":"The ITT population was defined as all participants randomized to the Atezolizumab+Gemcitabine+Carboplatin/Cisplatin arm or the Placebo+Gemcitabine+Carboplatin/Cisplatin arm in Stages 1 and 2, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Year 1","title":"PFS Event Free Rate","type":"SECONDARY","unitOfMeasure":"Percentage"}